Business Context and Reporting Period
Company: China Pharma Holdings, Inc. (CPHI)
Filing Type: Form 8-K (Current Report)
Report Date: December 4, 2025
Event: Entry into a Material Definitive Agreement for technology transfer.
Key Financial Metrics and Transaction Details
This filing reports a specific transaction rather than periodic financial results. Key metrics related to the transaction include:
- Transaction Value: $6.3 million.
- Consideration: Issuance of 3,500,000 restricted shares of Common Stock.
- Implied Share Price: $1.80 per share.
- Asset Acquired: Invention patent for a Captopril microcapsule and Method for Its Preparation.
- Counterparty: Lijie Tang (Transferor), a non-U.S. person.
Note: The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity for the reporting period.
Material Changes and Transaction Structure
On December 4, 2025, the Company's wholly owned subsidiary, Hainan Helpson Medical & Biotechnology Co., Ltd., entered into a Technology Transfer Agreement. The agreement involves the transfer of patent ownership from the Transferor to the subsidiary. In addition to the patent transfer, the Transferor is obligated to provide technical services, including product research and development, writing of registration materials, and registration applications.
Guidance, Risks, and Unusual Items
Regulatory Status: The 3,500,000 shares to be issued are unregistered securities. The issuance relies on the exemption from registration under Regulation S of the Securities Act, as the transaction was negotiated and consummated outside the United States with a non-U.S. person.
Risks: The shares are restricted. The success of the technology transfer depends on the Transferor's ability to deliver the agreed-upon technical services and registration materials.
Investor Verification Checklist
- Verify the current market price of CPHI common stock relative to the $1.80 transaction price.
- Confirm the status of the patent transfer and the validity of the Captopril microcapsule invention.
- Assess the potential dilution impact of issuing 3,500,000 new shares.
- Review the specific terms of the technical services to be provided by Lijie Tang.
- Check for any subsequent filings regarding the actual issuance of the restricted shares.